Literature DB >> 24231833

Henoch-Schönlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma.

Małgorzata Sobieszczańska1, Sławomir Tubek2, Dagmara Poplicha2, Anna Grabelus2, Jacek Pawełczak2.   

Abstract

A 52-y old man was admitted to our Department because of abdominal pains and diarrhea with fresh blood, with concomitant purpura over the whole body and edema of the both tarsal joints. The medical history of the patient included skin changes of similar character identified once 10-12 y before. The family history revealed prostate cancer (brother and father) and pulmonary carcinoma (mother and mother's sister). An administration of immunoglobulins in the course of HSP is a non-standard clinical procedure and in case of our patient--clinically effective. In the literature, we have found only few articles about intravenous immunoglobulin treatment for acute, adult-onset HSP and only one article about GI bleeding from colonic ecchymoses in HSP. In these cases HSP wasn't associated with prostate cancer. In the first article, authors had seen dramatic responses to intravenous immunoglobulin, like in the case presented by us. IV-IG acts as an immunomodulator by suppression of antibody production, Fc-receptor blockade and anti-idiotypic reaction. In our case, the last two mechanisms could be perceived as favorable effects of IV-IG.

Entities:  

Keywords:  GI bleeding; Henoch-Schönlein purpura; amiliar prostatic adenocarcinoma; diabetes; immunoglobulin treatment

Mesh:

Substances:

Year:  2014        PMID: 24231833      PMCID: PMC4185906          DOI: 10.4161/hv.27012

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

1.  GI bleeding from colonic ecchymoses associated with cutaneous ecchymoses over the lower extremities from leukocytoclastic vasculitis mediated by IgA deposition in Henoch-Schönlein purpura.

Authors:  Mitchell S Cappell; Mirela Onea; Mitual Amin
Journal:  Dig Dis Sci       Date:  2011-06       Impact factor: 3.199

Review 2.  Manipulating the immune system with immune globulin.

Authors:  J M Dwyer
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 3.  Should intravenous immunoglobulin G be first-line treatment for acute thrombotic thrombocytopenic purpura? Case report and review of the literature.

Authors:  D P Raniele; J A Opsahl; C M Kjellstrand
Journal:  Am J Kidney Dis       Date:  1991-08       Impact factor: 8.860

4.  Successful treatment of adult-onset Henoch-Schönlein purpura nephritis with high-dose immunoglobulins.

Authors:  A Kusuda; K Migita; M Tsuboi; M Degawa; N Matsuoka; M Tominaga; A Kawakami; Y Kawabe; T Taguchi; K Eguchi
Journal:  Intern Med       Date:  1999-04       Impact factor: 1.271

  4 in total
  5 in total

Review 1.  Urological Manifestations of Henoch-Schonlein Purpura: A Review.

Authors:  Amanda Dalpiaz; Richard Schwamb; Yimei Miao; Jacquelyn Gonka; Wayne Walzter; Sardar A Khan
Journal:  Curr Urol       Date:  2015-07-10

2.  Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice.

Authors:  Qian Xu; Zaiping Zhang; Zhiming Chen; Biying Zhang; Chanyuan Zhao; Yimin Zhang; Conghui Zhao; Xiaodong Deng; Yao Zhou; Yanyun Wu; Jiang Gu
Journal:  Cancer Manag Res       Date:  2019-03-07       Impact factor: 3.989

3.  Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn's-like Lymphoid Reaction.

Authors:  Viktoriya B Boncheva; Michael Linnebacher; Said Kdimati; Hannah Draper; Laurence Orchard; Ken I Mills; Gerald O'Sullivan; Mark Tangney; Barbara-Ann Guinn
Journal:  Biomolecules       Date:  2022-07-29

4.  Effect of Montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch-Schonlein purpura: A randomized controlled study.

Authors:  Xiaolin Gao; Ruixue Miao; Yuhong Tao; Xiuying Chen; Chaomin Wan; Ruizhen Jia
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

5.  Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells.

Authors:  Bogdana Kovalchuk; Anna S Berghoff; Matthia A Karreman; Katharina Frey; Manuel Piechutta; Manuel Fischer; Julia Grosch; Sabine Heiland; Michael O Breckwoldt; Frank Hilberg; Wolfgang Wick; Frank Winkler
Journal:  Clin Exp Metastasis       Date:  2020-09-12       Impact factor: 5.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.